Latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes – Pipeline Review, H1 2018, provides an overview of the Type 2 Diabetes pipeline landscape.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 2 Diabetes , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 10, 2, 29, 63, 72, 6, 220, 65 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 18 molecules, respectively.

Type 2 Diabetes pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned in Type 2 Diabetes are: Adocia SAS, Aegis Therapeutics LLC, AFFiRiS AG, Akcea Therapeutics Inc, Allist Shanghai Pharmaceutical Technology Co Ltd, Amarantus Bioscience Holdings Inc, Amgen Inc, Aphios Corp, Arecor Ltd, Arena Pharmaceuticals Inc, AstraZeneca Plc, AusBio Ltd, Avadel Pharmaceuticals Plc, Bayer AG, Betagenon AB, Betta Pharmaceuticals Co Ltd, Biocon Ltd, BioLingus AG, BioRestorative Therapies Inc, Biozeus, Biscayne Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Boston Therapeutics Inc, Braasch Biotech LLC, Bristol-Myers Squibb Co, C4X Discovery Holdings PLC, Cadila Healthcare Ltd, Cadila Pharmaceuticals Ltd, Caelus Health, Cardax Inc, Carmot Therapeutics Inc, Cellix Bio Pvt Ltd, Celon Pharma SA, Center Laboratories Inc, Chipscreen Biosciences Ltd, Chong Kun Dang Pharmaceutical Corp, Cinnagen Co, CJ HealthCare Corp, CohBar Inc, Concenter BioPharma Silkim Ltd, CymaBay Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, Dance Biopharm Inc, Delpor Inc, Diabetology (Products) Ltd, Diamyd Medical AB, Diasome Pharmaceuticals Inc, DiscoveryBiomed Inc, DNJ Pharma Inc, Dong-A Socio Holdings Co Ltd, Elcelyx Therapeutics Inc, Eli Lilly and Co, Eloxx Pharmaceuticals Inc, Energenesis Biomedical Co Ltd, Enteris BioPharma Inc, Enzene Biosciences Ltd, Enzo Biochem Inc, Epichem Pty Ltd, Eternygen GmbH, Evotec AG, F. Hoffmann-La Roche Ltd, Generex Biotechnology Corp,  Genexine Inc, Genfit SA, Genmedica Therapeutics SL, Genovate Biotechnology Co LTD, Geropharm LLC, Gilead Sciences Inc, GlaxoSmithKline Plc, Glucox Biotech AB, Hanmi Pharmaceuticals Co Ltd, Heptares Therapeutics Ltd, HitGen LTD, Hyundai Pharmaceutical Co Ltd, Immupharma Plc, Immuron Ltd, Inflazome Ltd, Innovative Targeting Solutions Inc, Inspyr Therapeutics Inc, InStar Technologies AS, Intarcia Therapeutics Inc, Intas Pharmaceuticals Ltd, Integral Molecular Inc, Intercept Pharmaceuticals Inc, Intrexon Corp, Ionis Pharmaceuticals Inc, Japan Tobacco Inc, Jeil Pharmaceutical Co Ltd, JHL Biotech Inc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Kadimastem Ltd, Kadmon Corp LLC, Kissei Pharmaceutical Co Ltd, Kowa Co Ltd, Laboratorios Silanes SA de CV, Lead Discovery Center GmbH, Leading BioSciences Inc, Lexicon Pharmaceuticals Inc, LG Chem Ltd, LipimetiX Development Inc, Longevity Biotech Inc, Luye Pharma Group Ltd, Magnus Life Ltd, MannKind Corp, Medesis Pharma SA, MedImmune LLC, Medlab Clinical Ltd, Merck & Co Inc, Mesoblast Ltd, Metabolic Solutions Development Company LLC, Metabolys SAS, Metacrine Inc, Mitsubishi Chemical Holdings Corp, Mitsubishi Tanabe Pharma Corp, Naia Ltd, Neurimmune Holding AG, NGM Biopharmaceuticals Inc, Novapeutics LLC, Novartis AG, NovaTarg Therapeutics Inc, Novo Nordisk AS, Omeros Corp, OPKO Biologics Ltd, OPKO Health Inc, Oramed Pharmaceuticals Inc, Original BioMedicals Co Ltd, Palatin Technologies Inc, Panacea Biotec Ltd, Paras Biopharmaceuticals Finland Oy, Peptron Inc, Pfizer Inc, PharmaCyte Biotech Inc, PharmaIN Corp, Pila Pharma AB, Poxel SA, Prometheon Pharma LLC, ProMetic Life Sciences Inc, Prothena Corp Plc, Purzer Pharmaceutical Co Ltd, Reata Pharmaceuticals Inc, reMYND NV, Renova Therapeutics Inc, Reset Therapeutics Inc, Rezolute Inc, Saniona AB, Sanofi, Sanwa Kagaku Kenkyusho Co Ltd, SATT Conectus Alsace SAS, SBI Pharmaceuticals Co Ltd, ScandiCure AB, Seres Therapeutics Inc, Serodus ASA, Serometrix LLC, Shenzhen HighTide Biopharmaceutical Ltd, Shionogi & Co Ltd, Sirona Biochem Corp, SJT Molecular Research SL, SK Chemicals Co Ltd, Sprint Bioscience AB, Sumitomo Dainippon Pharma Co Ltd, Suzuken Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Co Ltd, Teijin Pharma Ltd, The Medicines Company, Theracos Inc, Thermalin Diabetes LLC, Tiziana Life Sciences Plc, Toray Industries Inc, Torrent Pharmaceuticals Ltd, Transgene Biotek Ltd, TTY Biopharm Company Ltd, Twoxar Inc, Uni-Bio Science Group Ltd, ViaCyte Inc, Vichem Chemie Research Ltd, Vicore Pharma AB, Viking Therapeutics Inc, Vivus Inc, vTv Therapeutics Inc, Vybion Inc, XBiotech Inc, XERIS Pharmaceuticals Inc, XL-protein GmbH, XOMA Corp, XuanZhu Pharma Co Ltd, Yabao Pharmaceutical Group Co Ltd, Yuhan Corp, Zafgen Inc, Zealand Pharma AS

Request for a Sample Copy of this Research Report at:


  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes.
    2. The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources.
    3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    5. The pipeline guide reviews key companies involved in Type 2 Diabetes therapeutics and enlists all their major and minor projects.
    6. The pipeline guide evaluates Type 2 Diabetes therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    8. The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes

Browse full Report at:

Reasons to buy this Report:

1. procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
2. Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes.
Classify potential new clients or partners in the target demographic.
3. Develop tactical initiatives by understanding the focus areas of leading companies.
4. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
5. Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics.
6. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
7. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Important Points Covered In Table of Content are:

Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.